Introduction
Numerous studies have reported that the adenomatous polyposis coli (APC) tumour suppressor has a critical role in protecting against chromosome instability (CIN) . This was first established in embryonic stem cells lacking APC, which rapidly became aneuploid in vitro (Fodde et al., 2001; Kaplan et al., 2001) . Since then, recent reports have suggested that APC has a critical role in the spindle assembly checkpoint (SAC; Dikovskaya et al., 2001) , kinetochore-microtubule attachment and cytokinesis (Caldwell et al., 2007) . However, a number of these phenotypes are relatively subtle (although very reproducible) and others appear to be contentious and possibly cell context specific (Tighe et al., 2004; Rusan and Peifer, 2008) . Therefore, assessing whether the role of APC in protecting against chromosomal instability is important for tumour initiation or progression has been difficult. Also, it has been difficult to distinguish phenotypes because of specific functions of APC from secondary consequences of WNT signalling deregulation following APC loss.
The main function of APC in chromosomal instability is thought to be because of its ability to bind microtubules (Dikovskaya et al., 2004) . APC has been shown to unambiguously localize to microtubules, where it interacts with EB1 (Su et al., 1995) , and microtubule-kinetochore attachments, where it is thought to be important for the SAC (possibly through an interaction with BubR1 and Bub1 (budding uninhibited by benzimidazoles 1)) . However, there is conflicting evidence about the role of APC in the SAC (as measured by the arrest caused by microtubule poisons), with one study showing a reduction (although not a block) in arrest after Nocodazole in U2OS cells, whereas another study failing to find an impact of APC depletion (Green et al., 2005; Draviam et al., 2006; Dikovskaya et al., 2007) . One of the difficulties in comparing these studies is that many have been performed in cell lines where other genes in the spindle checkpoint could have been mutated, and therefore removing APC may be revealing secondary differences. Furthermore, different experimental conditions may have different effects on different cells lines. Also, it is clear from studies that cells in culture (even primary cells) have a much greater propensity to acquire chromosome instability than matched cells in vivo (Uetake and Sluder, 2004) .
Therefore, we decided to test the response of APCdeficient cells to two mitotic spindle poisons, Taxol and Vinorelbine (as a measure of the mitotic spindle checkpoint), immediately after APC is lost in vivo. Both Taxol and Vinorelbine bind to the b-subunit of tubulin but cause different consequences: Taxol inhibits microtubule depolymerization and hence stabilizes microtubules, whereas Vinorelbine depolymerizes microtubules and therefore destabilizes microtubules (Krikorian and Breillout, 1991; Nogales et al., 1999) . The phenotype of APC deletion in the intestine is dramatic: co-incident with b-catenin activation, there is a marked increase in enterocyte proliferation (and apoptosis) and decrease in migration and differentiation . We define this as a crypt progenitor cell-like phenotype. In this system, co-deletion of c-Myc rescues all of the phenotypes of APC loss and thus, despite the presence of nuclear b-catenin, the majority of WNT target genes are not activated . In conclusion, APC and c-Myc co-deletion allows an investigation of the APC-loss phenotype separate from WNT target gene activation.
In this study we definitively show that rather than being a general mitotic SAC protein like Bub1, APC is only required for the response to Taxol at low doses and is not required for the arrest in response to the microtubule-destabilizing agent Vinorelbine. Moreover, this role of APC at low Taxol doses is independent of WNT signalling.
Results

APC-deficient cells are resistant to 10 mg/kg Taxol
To characterize the SAC within intestinal enterocytes in vivo, we injected wild-type mice with 10 mg/kg of Taxol and harvested mice at 30 min and at 1, 2, 3, 6, 9, 12 and 24 h. A significant induction of arrested mitotic figures was seen in wild-type mice from 3 h (see Figure 1a , Supplementary Figure S1A) . By 24 h, the levels of mitotic figures had returned to normal levels. Furthermore, bromodeoxyuridine labelling at 24 h shows reduced numbers of bromodeoxyuridine-positive cells following Taxol treatment compared with vehicle treatment (Supplementary Figure S1C) .
Given this clear onset of arrest in wild-type mice, we therefore decided to investigate whether the onset and severity of the arrest was affected by APC deficiency. Control (AhCre þ APC þ / þ ) and experimental (AhCre þ APC fl/fl ) mice were given three injections of the Cre inducer b-napthoflavone to induce recombination, and 4 days later mice were injected with 10 mg/kg Taxol and harvested either 3, 6 or 9 h later. At all three time points, intestinal enterocytes lacking APC showed significantly fewer mitotic figures than APC-proficient tissue treated with Taxol ( Figures 1c and e , Supplementary Figure S2A ).
Given the possibility that changes in this mitotic checkpoint may be because of alterations in WNT signalling, we investigated the levels of nuclear b-catenin (the most reliable measure of activated WNT signalling in vivo) in AhCre þ APC fl/fl intestinal enterocytes treated with Taxol and found no difference when compared with vehicle-treated AhCre þ APC fl/fl mice ( Figure 2a) . A key event downstream of b-catenin nuclear accumulation is the expression of c-MYC, which drives the hyperproliferation, loss of migration and differentiation, and increase in apoptosis was seen following APC deletion . When APC and c-MYC are co-deleted, nuclear b-catenin is still observed but intestinal crypts look ostensibly normal with wild-type levels of proliferation, apoptosis, migration and differentiation. Hence, to further test our hypothesis we investigated whether doubly mutant AhCre þ APC fl/fl Myc fl/fl were also resistant to 10 mg/kg Taxol treatment. If this were so, it would prove that APC loss has an impact on the cell even in the absence of an active WNT pathway. Figure 2b shows Myc þ / þ enterocytes. This lack of arrest strongly argues against a role of other WNT target genes in the failed activation of the mitotic checkpoint.
To directly test whether increasing WNT signalling per se leads to an impaired response to Taxol, we investigated whether intestinal enterocytes that lacked both glycogen synthase kinase 3 (GSK3) a and GSK3 b showed a normal response to Taxol. Co-deletion of GSK3 a and b produces an intestinal phenotype comparable to APC deletion (S Radulescu et al., in preparation) with enlarged intestinal crypts with nuclear b-catenin. When these mice were treated with 10 mg/kg of Taxol, they showed a robust arrest to Taxol (Figures 2d and e), showing unambiguously that deregulated WNT signalling on its own is not sufficient to impair the response to Taxol. Figure S2B) . Therefore, these data show that at high levels of Taxol, the SAC can be established without APC, and thus APC is not essential for the mitotic spindle checkpoint.
Given previous data suggesting that microtubules in APC-deficient cells are destabilized , we hypothesized that APC deficiency might lead to a reduced stabilization of microtubules in response to Taxol and that this may be one reason for the lack of arrest. Consistent with this theory, mitotic microtubules in wild-type mice were stabilized in response to Taxol at 10 and 20 mg/kg (Figure 3d , note the bundling of microtubules in the centre of the cell in a star pattern). In contrast, APC-deficient intestine only showed stabilized microtubules in mitosis at 20 mg/kg (white arrows), whereas at 10 mg/kg normal mitotic distribution of microtubules was observed (orange arrow).
APC-deficient intestinal cells arrest robustly in response to Vinorelbine and do not phenocopy deletion of BUB1
If indeed the failed response to low levels of Taxol is because of destabilized microtubules in APC-deficient mice, this leads to two predictions: first, APC-deficient cells should arrest robustly with microtubule-destabilizing (nX3) were killed 6 h post-injection and the levels of mitotic arrest and apoptosis in intestinal crypts were scored using haematoxylin and eosin (H þ E) staining. Mitotic and apoptotic index was expressed as percentage of cells per crypt. As intestinal enterocytes enter G2 phase, they move out of the crypt lining and into the lumen where they will undergo mitosis and cytokinesis before retuning back to the single cell layer crypt lining. However, enterocytes can undergo apoptosis anywhere in the crypt. (a) Representative H þ E staining of crypts from WT mice treated with Taxol 10 mg/kg and killed at 3, 6, 9 or 24 h post-injection. agent Vinorelbine and, second, inactivation of a key component of the mitotic SAC should show a different response to mitotic poisons than APC deletion, namely failed arrest in response to both agents independent of drug concentration.
To test the first possibility, we investigated the arrest in wild-type and APC-deficient intestines following two doses of Vinorelbine: 5 and 10 mg/kg. Vinorelbine at 5 mg/kg induces a weak arrest, whereas at 10 mg/kg it induces a robust arrest at 6 h following delivered intravenous injection (Figures 4a and c and Supplementary Figure  S3 ). As predicted, even at low doses, the level of arrest was equivalent between wild-type and APC-deficient intestines. Moreover, staining for microtubules showed destabilized microtubules in mitotic figures of both genotypes after treatment (Figure 4b ). These data clearly show that APC is not required as a general mitotic spindle checkpoint protein (as determined by spindle poisons). APC and the spindle assembly checkpoint S Radulescu et al Next, to ensure that the mitotic SAC is required for arrest in vivo in response to both Taxol and Vinorelbine, we investigated whether intestines deficient for Bub1 can arrest in response to these drugs. Bub1 deficiency has a profound effect on intestinal homeostasis at later time points (Radulescu et al., in preparation) ; however, after 2 days of Bub1 deletion, no marked phenotypes are observed. Figure 4d and Supplementary Figure S4 show that intestinal enterocytes lacking Bub1 are unable to undergo mitotic arrest following either low-or highdose Taxol or Vinorelbine. Therefore, this shows that although inactivating a bona fide SAC protein abrogates mitotic arrest in response to either of the mitotic poison, inactivating APC does not. In turn, this implies that APC is not a bona fide SAC protein.
High doses of Taxol suppress tumourigenesis in the APC
Min/ þ mouse We wished to address if the resistance to Taxol of the APC-deficient intestine has functional consequences for tumourigenesis. To this end we investigated whether Taxol affects tumourigenesis in the APC Min/ þ mouse (Moser et al., 1990) . On a purebred C57BL6J background, these mice develop over 100 adenomas by 100 days of age, with tumour initiation occurring by loss of the remaining APC wild-type allele. Therefore, we aged three cohorts of 20 APC Min/ þ mice: vehicle-treated, 10 mg/kg (every 2 weeks) Taxol and 20 mg/kg (every 2 weeks) Taxol. These mice were harvested at 100 days of age and tumour number and size was scored. As shown in Figure 5a , 10 mg/kg did not cause a APC and the spindle assembly checkpoint S Radulescu et al significant reduction in adenoma multiplicity at 100 days. Figure 5b shows in turn that 20 mg/kg caused a significant reduction in tumour multiplicity. Tumour size was also significantly reduced in mice treated with 20 mg/kg Taxol (Figure 5d ). Therefore, in this study we show that the ability to arrest in response to Taxol directly predicts whether Taxol will suppress adenoma formation. Given that APC Min/ þ mice were only injected with Taxol every 2 weeks, we also investigated whether a more frequent Taxol treatment regime had a more dramatic impact of tumourigenesis. Figure 5c shows a strong reduction in tumour number when mice were treated three times every 2 weeks, which was significantly lower than mice that had been treated only once every 2 weeks.
Finally, we investigated whether this regime of Taxol could suppress more aggressive intestinal tumours induced by combined APC and PTEN (phosphatase and tensin homologue) deficiency (Marsh et al., 2008) . Cohorts of AhCreER þ APC fl/ þ PTEN fl/fl were treated with 20 mg/kg Taxol or vehicle three times every 2 weeks and harvested 60 days following Cre induction. In this model, both b-napthoflavone and Tamoxifen are required to activate Cre recombinase and tumours are formed after loss of the APC allele. In these mice too, intestinal tumourigenesis was strongly suppressed by treatment with Taxol (Figure 5e ).
Discussion
There has been much debate over the role that APC has in the SAC. Using an in vivo approach, we have clarified the role of APC in this process. Our data show that APC deficiency in vivo impairs the arrest response to low but not high levels of Taxol. These data somewhat explain the previous contrasting in vitro data. The study by Draviam et al. (2006) used a level of Nocodazole that induced very high levels of arrest (60-80%) and found no impact of APC loss, whereas the study of Dikovskaya et al. (2007) induced a much lower level of arrest (6-12%) and revealed a role for APC in the SAC (6-12% cells). Therefore, the role of APC in response to microtubule-stabilizing agents in vivo and in vitro is only revealed when working below the threshold where the checkpoint is fully engaged. In spite of the fact APC deletion affects the response to microtubule-stabilizing agents, the SAC is by no means absent in these cells. High levels of Taxol induce a robust mitotic arrest both in the presence or absence of APC, as does Vinorelbine treatment (both at high and low levels). When comparing SAC activation in APCdeficient and Bub1-deficient cells, it is obvious that Bub1 deletion completely abrogates the ability of the cell to pause in mitosis. This suggests that APC is not a member of the SAC and probably affects the checkpoint activity indirectly. Indeed, the most likely reason why APC-deficient cells do not respond to microtubulestabilizing agents is because these cells possess destabilized microtubules and thus higher levels of stabilizing agents are required to initiate arrest. In this study, we have also shown that the impaired arrest is unlikely to be down to activation of WNT signalling following APC loss, as deletion of GSK3 a and b, which activate WNT signalling, does not affect the mitotic response to Taxol. Moreover, co-deletion of APC and cMYC still results in Taxol insensitivity at low doses, despite a reduction in most WNT target genes.
In this study we have also shown that the ability to arrest in response to Taxol directly predicts whether Taxol will suppress adenoma formation. This result is in agreement with in vitro data showing that activation of the mitotic checkpoint is required following Taxol treatment in order to kill cancer cells (Gascoigne and Taylor, 2008; Huang et al., 2009) . Furthermore, these data raise the possibility that doses of taxanes that induce arrest in colorectal cancer in vivo may be a useful treatment option. However, within colorectal cancer the multiple drug resistance pump is often deregulated, which may prevent Taxol concentration from reaching sufficiently high levels in tumours to cause arrest (Linn and Giaccone, 1995) . In the future, this may not present a problem with new microtubule-stabilizing agents (now in clinical trials) coming on line that are not recognized by multiple drug resistance pumps, for example, Patupilone (Novartis, Frimley, UK). Thus, it will be of great interest to determine if this agent has chemopreventative effects in mouse models of intestinal tumourigenesis like those used in this study.
In summary, using an in vivo model where we synchronously deleted APC, we defined a role for APC in the response to MT poisons. Given that this response is a good indicator of the SAC in vivo, we have shown that unlike Bub1, APC is not a general mediator of the SAC. Instead, it is required for the efficient arrest at lower doses of Taxol, suggesting that APC is involved in the sensitivity of the SAC activation. This reconciles published data because it confirms that the amount of drug used to treat cells and their inherent threshold for activation of this checkpoint is crucial when making comparisons between different experiments. Importantly, our data with GSK3 loss suggest that this function of APC is independent of its role in WNT signalling, although we cannot absolutely rule out a contribution from activation of T-cell factor-regulated transcription. Instead, it may be because of the destabilization of microtubules in APC-deficient cells. Our finding that the onset of arrest in APC-deficient cells directly predicts responsiveness of the APC Min/ þ mice to Taxol is clinically important.
Materials and methods
Ethics statement
All mouse experiments were performed under the UK Home Office guidelines.
Mouse colonies
Outbred male mice from 6 to 12 weeks of age were used, which were segregating for the C57BL6J and S129 genomes (five generations C57Bl6J). The alleles used were as follows: APC 580S (Shibata et al., 1997) , Myc fl/fl (Baena et al., 2005) , AhCre , AhCreER , PTEN fl/fl (Suzuki et al., 1998 (Suzuki et al., , 2003 , Bub1 fl/fl (Perera et al., 2007) , GSK3 a fl/fl and GSK3 b fl/fl (Patel et al., 2008) . All APC Min/ þ experiments were performed on mice that were 100% C57BL6J (Moser et al., 1990) .
Tissue isolation
To induce recombination, mice were given three injections (intraperitoneal) spaced 4 h apart of b-napthoflavone (Sigma, Dorset, UK) at 80 mg/kg concentration . At the appropriate time point, mice were killed and the small intestine removed and flushed with water (at least three mice were used for each experiment). A number of studies have suggested that Cre recombinase expression may induce DNA damage. In this study, as the Cre is only induced on the first day of the experiment (within the intestine crypt and stem cells), by the time the mice are treated with microtubule poisons (4 days later), Cre is no longer expressed .
Microtubule poison experiments
Taxol (Paclitaxel, Mayne Pharma, Royal Leamington Spa, UK), a microtubule stabilizer, and Vinorelbine (Navelbine, Pierre Fabre, Winchester, UK), a microtubule destabilizer, were used as microtubule poisons. All experiments were performed on group sizes of at least three mice each. For short-term experiments, APC was deleted from the intestinal epithelium by Cre-mediated recombination and mice were treated with Taxol 10, 20 or 30 mg/kg (intraperitoneal) and harvested 30 min or at 1, 2, 3, 6, 9, 12, 15 or 24 h later. Vinorelbine was used at 5 or 10 mg/kg concentration and delivered intravenously. For long-term experiments, cohorts of APC Min/ þ mice (n ¼ 20) were given one Taxol injection (intraperitoneal) of 10 or 20 mg/kg every 2 weeks from 45 days of age. Mice were harvested at 100 days of age and the number of tumours was scored in both the small and large intestine. For the dose that showed the highest impact on tumour number, the treatment was increased to three Taxol injections a week (every other day) every 2 weeks. For the invasive intestinal tumour model, AhCreER þ APC fl/ þ PTEN fl/fl mice were given four daily injections of b-napthoflavone and Tamoxifen (Sigma) at 80 mg/kg concentration each . Taxol 20 mg/kg treatment (three intraperitoneal injections a week on alternative days) started 2 weeks after the last injection and mice were killed 60 days after induction.
